Literature DB >> 15201348

Botulinum toxin in clinical practice.

J Jankovic1.   

Abstract

Botulinum toxin, the most potent biological toxin, has become a powerful therapeutic tool for a growing number of clinical applications. This review draws attention to new findings about the mechanism of action of botulinum toxin and briefly reviews some of its most frequent uses, focusing on evidence based data. Double blind, placebo controlled studies, as well as open label clinical trials, provide evidence that, when appropriate targets and doses are selected, botulinum toxin temporarily ameliorates disorders associated with excessive muscle contraction or autonomic dysfunction. When injected not more often than every three months, the risk of blocking antibodies is slight. Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201348      PMCID: PMC1739107          DOI: 10.1136/jnnp.2003.034702

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  95 in total

1.  Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.

Authors:  J Jankovic; K D Vuong; J Ahsan
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

2.  Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.

Authors:  G-Y R Hsiung; S K Das; R Ranawaya; A-L Lafontaine; O Suchowersky
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

Review 3.  Botulinum toxin and other new approaches to migraine therapy.

Authors:  Avi Ashkenazi; Stephen D Silberstein
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

Review 4.  Dystonia: medical therapy and botulinum toxin.

Authors:  Joseph Jankovic
Journal:  Adv Neurol       Date:  2004

Review 5.  Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.

Authors:  James E Frampton; Stephanie E Easthope
Journal:  Am J Clin Dermatol       Date:  2003       Impact factor: 7.403

6.  Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response.

Authors:  Behzod Z Dolimbek; Joseph Jankovic; M Zouhair Atassi
Journal:  Immunol Invest       Date:  2002 Aug-Nov       Impact factor: 3.657

7.  Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.

Authors:  Patrick G Foran; Nadiem Mohammed; Godfrey O Lisk; Sharuna Nagwaney; Gary W Lawrence; Eric Johnson; Leonard Smith; K Roger Aoki; J Oliver Dolly
Journal:  J Biol Chem       Date:  2002-10-14       Impact factor: 5.157

8.  Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.

Authors:  M K Naumann; H Hamm; N J Lowe
Journal:  Br J Dermatol       Date:  2002-12       Impact factor: 9.302

9.  A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.

Authors:  William G Ondo; Christine Hunter; Warren Moore
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910

10.  Molecular targets of botulinum toxin at the mammalian neuromuscular junction.

Authors:  Dorothy D Whelchel; Tonia M Brehmer; Paula M Brooks; Neely Darragh; Julie A Coffield
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

View more
  93 in total

1.  Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats.

Authors:  Ivica Matak; Ivana Stracenski; Zdravko Lacković
Journal:  J Neural Transm (Vienna)       Date:  2012-06-17       Impact factor: 3.575

Review 2.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

3.  SNARE tagging allows stepwise assembly of a multimodular medicinal toxin.

Authors:  Frédéric Darios; Dhevahi Niranjan; Enrico Ferrari; Fan Zhang; Mikhail Soloviev; Andreas Rummel; Hans Bigalke; Jason Suckling; Yuri Ushkaryov; Nikolay Naumenko; Anastasia Shakirzyanova; Rashid Giniatullin; Elizabeth Maywood; Michael Hastings; Thomas Binz; Bazbek Davletov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

Review 4.  Bioterrorism and the Role of the Clinical Microbiology Laboratory.

Authors:  Elizabeth Wagar
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

5.  A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites.

Authors:  Christiane G Frick; Heidrun Fink; Manfred Blobner; Jeevendra Martyn
Journal:  Anesth Analg       Date:  2011-10-14       Impact factor: 5.108

Review 6.  Botulinum toxin therapy for cervical dystonia.

Authors:  J Jankovic
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

7.  Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.

Authors:  R Eleopra; V Tugnoli; R Quatrale; O Rossetto; C Montecucco; D Dressler
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 8.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

9.  Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics.

Authors:  Navaneetha Santhanam; Lee Kumanchik; Xiufang Guo; Frank Sommerhage; Yunqing Cai; Max Jackson; Candace Martin; George Saad; Christopher W McAleer; Ying Wang; Andrea Lavado; Christopher J Long; James J Hickman
Journal:  Biomaterials       Date:  2018-02-27       Impact factor: 12.479

10.  Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays.

Authors:  Paul T Bremer; Michael Adler; Cecilia H Phung; Ajay K Singh; Kim D Janda
Journal:  J Med Chem       Date:  2017-01-03       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.